An open-label expanded access study of trifluridine/tipiracil for metastatic colorectal cancer.

被引：4
|
作者：
Mayer, Robert J.
Grothey, Axel
Hochster, Howard S.
Cohen, Steven J.
Vukovic, Vojislav M.
Makris, Lukas
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
    Li, Rongrong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Liu, Zhen-yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
    Chida, Keigo
    Kotani, Daisuke
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Shitara, Kohei
    Kojima, Takashi
    Taniguchi, Hiroya
    Watanabe, Jun
    Endo, Itaru
    Yoshino, Takayuki
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [23] Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
    Fumet, Jean-David
    Roussot, Nicolas
    Bertaut, Aurelie
    Limagne, Emeric
    Thibaudin, Marion
    Hervieu, Alice
    Zanetta, Sylvie
    Borg, Christophe
    Senellart, Helene
    Pernot, Simon
    Thuillier, Frederic
    Carnot, Aurelien
    Mineur, Laurent
    Chibaudel, Benoist
    Touchefeu, Yann
    Martin-Babau, Jerome
    Jary, Marine
    Labourey, Jean-Luc
    Rederstorff, Emilie
    Lepage, Come
    Ghiringhelli, Francois
    FUTURE ONCOLOGY, 2024, 20 (38) : 3077 - 3085
  • [24] Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe M.
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik P.
    Benhadji, Karim A.
    Amellal, Nadia
    Leger, Catherine
    Vidot, Loick
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (18): : 1657 - 1667
  • [25] A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer
    Zou, Jiayun
    Wang, Yuanyuan
    Xu, Jiayu
    Li, Jinna
    Wang, Tianzhuo
    Zhang, Ying
    Bai, Yibo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [26] Safety and efficacy of trifluridine/tipiracil monotherapy in metastatic colorectal cancer
    Aparicio Rubio, C.
    Monteagudo Santolaya, E.
    Cornejo Uixeda, S.
    Prieto Castello, M.
    Antonino de la Camara, G.
    Quintana Vergara, B.
    Sanchez Alcaraz, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 373 - 374
  • [27] Trifluridine/tipiracil in metastatic colorectal cancer: a guide to its use
    Lyseng-Williamson K.A.
    Burness C.B.
    Duggan S.T.
    Drugs & Therapy Perspectives, 2017, 33 (3) : 110 - 118
  • [28] A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.
    Hollebecque, Antoine
    Argiles, Guillem
    Andre, Thierry
    Cervantes, Andres
    Leger, Catherine
    Valette, Aude
    Amellal, Nadia
    Fougeray, Ronan
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Horasawa, Satoshi
    Kaneko, Asumi
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Bando, Hideaki
    Taniguchi, Hiroya
    Shitara, Kohei
    Kojima, Takashi
    Tsuji, Akihito
    Yoshino, Takayuki
    BMC CANCER, 2019, 19 (01)
  • [30] Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
    Price, T. J.
    Burge, M.
    Chantrill, L.
    Chua, Y. J.
    Horvath, L.
    McLachlan, S-A.
    Pavlakis, N.
    Shapiro, J.
    Thavaneswaran, S.
    Tran, B.
    Yip, D.
    Tancock, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S1283 - S1283
12345